PO Is OK for COPD -- Follow the Guidelines!

Phillips, Barbara A.
August 2010
Internal Medicine Alert;8/15/2010, Vol. 32 Issue 15, p115
There is no difference in rates of treatment failure, death, or readmission for COPD between patients treated with oral or intravenous steroids for exacerbation of COPD, but the IV route may be associated with increased cost and length of stay.


Related Articles

  • Journal Watch.  // Pulse;7/19/2007, Vol. 67 Issue 28, p13 

    The article offers news briefs related to medicine in Great Britain. One study shows that the use of inhaled steroids in chronic obstructive pulmonary disease (COPD) raise the risk of hospital admission for pneumonia. Another study found that older diabetes drugs are as effective or better than...

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // OB/GYN Clinical Alert;Nov2008 Pharmacology Watch, p1 

    The article offers news briefs related to pharmacology in the U.S. The Food and Drug Administration (FDA) has issued an "Early Communication" about an ongoing safety review of tiotropium (Spriva®), an inhaled anticholinergic for treating chronic obstructive pulmonary disease (COPD)....

  • The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide? van der Molen, Thys; Kocks, Janwillem W. H. // Primary Care Respiratory Society UK;6/1/2014, p1 

    The author reflects on the effectiveness and safety of using ciclesonide, an inhaled corticosteroids (ICS) agent on patients with asthma. Topics include the prescription of ICS in patients with chronic obstructive pulmonary disease (COPD), the introduction of ICS in the clinical prctice in 1970,...

  • Roflumilast: A new phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease. Baker, Erica L.; Baker, William L. // Formulary;Jan2010, Vol. 45 Issue 1, p6 

    The article discusses the use of roflumilast for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). Roflumilast is a phosphodiesterase 4 inhibitor under review by the U.S. Food and Drug Administration (FDA). Studies demonstrate that roflumilast improves lung...

  • Forest and Almirall Announce Submission of New Drug Application for Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).  // Biomedical Market Newsletter;7/5/2011, p249 

    The article reports on the new drug application (NDA) for aclidinium bromide submitted by Almirall SA and Forest Laboratories Inc. to the U.S. Food and Drug Administration (FDA). It states that aclidinium bromide is a long-acting inhaled antimuscarinic drug for the treatment of chronic...

  • Umeclidinium-vilanterol: First once-daily dual bronchodilator for COPD. YOUNG, CARA ALDRIDGE // Pharmacy Today;Feb2014, Vol. 20 Issue 2, p28 

    The article reports on the approval for umeclidinium-vilanterol powder by the U.S. Food & Drug Administration as a dual bronchodilator for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). The contraindications of the use of the drug in patients with asthma are...

  • LABAs improve elderly survival rates.  // Pulse;5/11/2011, Vol. 71 Issue 17, p7 

    The article discusses research being done on the effectiveness of long-acting agonists for the treatment chronic obstructive pulmonary disease (COPD) which references a study published in "Annals of Internal Medicine."

  • Tiotropium asthma boost.  // Pulse;9/22/2010, Vol. 70 Issue 27, p4 

    The article discusses the result of a study which reveals that chronic obstructive pulmonary diseases (COPD) drug tiotropium boosts the dose of inhaled steroids in the management of adult with asthma.

  • Roflumilast.  // Drugs;2010, Vol. 70 Issue 12, p1615 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics